SCHEMBL2173548

SCHEMBL2173548

COc1cccc(NC(=O)c2n[nH]c3c2COc2ccccc2-3)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.56
HIF1A Q16665 2/20 0.49
HTT P42858 2/20 0.48
TSHR P16473 1/20 0.48
NPC1 O15118 6/20 0.47
RAB9A P51151 5/20 0.47
PKM P14618 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
NLRP3 Q96P20 1/20 0.46
GRM4 Q14833 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
MAPK10 P53779 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HSP90AA1 P07900 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172661 0.89 CDK2 (0.54) FLT3HIF1ATSHRNPC1RAB9A
SCHEMBL2171314 0.80 GPBAR1 (0.47) HIF1ANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2173401 0.80 MEN1 (0.54) HIF1ANPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL2542966 0.80 MAPT (0.70) HIF1ANPC1RAB9APKMSMN1; SMN2
SCHEMBL2548371 0.79 ALDH1A1 (0.48) FLT3HTTNPC1RAB9AKDM4E
SCHEMBL2176261 0.77 GRM5 (0.46) NPC1RAB9APKMKDM4EALDH1A1
SCHEMBL6644918 0.76 CDK2 (0.54) SMN1; SMN2KMT2AMEN1RXFP1MAPT
SCHEMBL3518121 0.73 ALDH1A1 (0.43) HTTTSHRNPC1RAB9AKDM4E
SCHEMBL3747711 0.73 KMT2A (0.44) NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL2171482 0.73 KDM4E (0.59) NPC1RAB9AKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US claimed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP claimed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO claimed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 FLT3 857/4885HIF1A 4550/4885HTT 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.